Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study.
Jackson, Melinda L, Butt, Henry, Ball, Michelle et al. · Sleep science (Sao Paulo, Brazil) · 2015 · DOI
Quick Summary
This small study tested whether reducing certain bacteria in the gut could improve sleep in people with ME/CFS. Researchers gave 21 participants a short course of antibiotics and measured changes in their gut bacteria and sleep. Seven participants showed significant reduction in a type of bacteria called Streptococcus, and these people did sleep better after treatment. However, most participants' gut bacteria returned to their original state, suggesting the antibiotic effects didn't last.
Why It Matters
Since ME/CFS patients commonly experience both severe sleep disturbance and gut dysbiosis, this study explores a potential mechanistic link between these two debilitating symptoms. Understanding whether restoring gut bacterial balance could improve sleep offers a novel therapeutic avenue for a population with limited treatment options. The findings suggest targeted microbiota modulation warrants further investigation as a possible adjunctive treatment.
Observed Findings
Seven of 21 participants (responders) achieved clinically significant reduction in faecal Streptococcus to <6% after erythromycin treatment.
Responders showed statistically significant increases in objective sleep time measured by actigraphy (p=0.028) compared to non-responders.
Lower Streptococcus counts were significantly associated with improved vigour/energy scores (ρ=-0.90, p=0.037).
Higher Lactobacillus levels correlated with poorer mood in both responders and the entire study group.
Most participants (non-responders) did not sustain microbiota changes after the 6-day antibiotic course.
Inferred Conclusions
Reduction of gram-positive Streptococcus in gut microbiota is associated with objective improvements in sleep duration in ME/CFS patients.
The gut-sleep-mood axis may involve specific bacterial taxa, with Streptococcus and Lactobacillus playing potentially important roles.
Short-term antibiotic intervention is insufficient to create lasting microbiota changes in most ME/CFS patients, suggesting alternative microbiota modification strategies may be needed.
Further mechanistic research linking specific gut organisms to sleep and mood disturbances in ME/CFS is warranted.
Remaining Questions
What This Study Does Not Prove
This study does not establish that gut dysbiosis causes poor sleep in ME/CFS, only that they may be associated in some patients. The open-label design without placebo control cannot rule out placebo effects on subjective outcomes. The short-term antibiotic approach was largely unsustainable, so these findings do not support erythromycin as a practical long-term treatment for most ME/CFS patients.
Tags
Symptom:Unrefreshing SleepFatigue
Biomarker:Blood Biomarker
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall SampleExploratory Only
What mechanisms explain how reduced Streptococcus improves sleep—are microbial metabolites, intestinal barrier function, or immune signalling involved?
Could sustained or alternative microbiota modification approaches (probiotics, dietary interventions, phage therapy) produce lasting improvements in sleep?
Do the sleep improvements result from direct microbiota effects or from secondary changes in immune function, inflammation, or circadian biology?
Which specific ME/CFS patients are most likely to benefit from microbiota-targeted interventions, and are there biomarkers predicting responders versus non-responders?